

Research article

Open Access

## Evidence for cell autonomous API function in regulation of *Drosophila* motor-neuron plasticity

Subhabrata Sanyal\*<sup>1</sup>, Radhakrishnan Narayanan<sup>1</sup>, Christos Consoulas<sup>2</sup> and Mani Ramaswami\*<sup>1,3</sup>

Address: <sup>1</sup>Department of Molecular & Cellular Biology, Box 210106 University of Arizona, 1007 E. Lowell Street, Tucson AZ 85721, USA, <sup>2</sup>Department of Experimental Physiology, Medical School, University of Athens, Athens, Greece and <sup>3</sup>ARL Division of Neurobiology, University of Arizona, Tucson AZ 85721, USA

Email: Subhabrata Sanyal\* - sanyal@u.arizona.edu; Radhakrishnan Narayanan - rnarayan@u.arizona.edu; Christos Consoulas - cconsoul@med.uoa.gr; Mani Ramaswami\* - mani@u.arizona.edu

\* Corresponding authors

Published: 11 September 2003

Received: 01 April 2003

BMC Neuroscience 2003, 4:20

Accepted: 11 September 2003

This article is available from: <http://www.biomedcentral.com/1471-2202/4/20>

© 2003 Sanyal et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

### Abstract

**Background:** The transcription factor API mediates long-term plasticity in vertebrate and invertebrate central nervous systems. Recent studies of activity-induced synaptic change indicate that API can function upstream of CREB to regulate both CREB-dependent enhancement of synaptic strength as well as CREB-independent increase in bouton number at the *Drosophila* neuromuscular junction (NMJ). However, it is not clear from this study if API functions autonomously in motor neurons to directly modulate plasticity.

**Results:** Here, we show that Fos and Jun, the two components of API, are abundantly expressed in motor neurons. We further combine immunohistochemical and electrophysiological analyses with use of a collection of enhancers that tightly restrict API transgene expression within the nervous system to show that API induction or inhibition in, but not outside of, motor neurons is necessary and sufficient for its modulation of NMJ size and strength.

**Conclusion:** By arguing against the possibility that API effects at the NMJ occur via a polysynaptic mechanism, these observations support a model in which API directly modulates NMJ plasticity processes through a cell autonomous pathway in the motor neuron. The approach described here may serve as a useful experimental paradigm for analyzing cell autonomy of genes found to influence structure and function of *Drosophila* motor neurons.

### Background

Long-term forms of synaptic plasticity are distinguished from transient short-term forms by a requirement for new gene expression [1]. The nature of the transcriptional switch that interprets and responds to synaptic signals that trigger persistent changes to synapses, remains intensely studied but yet poorly established. In the consensus model, ERK-dependent phosphorylation of CREB

initiates CREB-dependent transcription of a first wave of immediate early genes including transcription factors such as Fos and Jun that dimerize to form AP1. Immediate-early transcription-factors, either independently or in collaboration with CREB, then regulate waves of gene expression that underlie persistent changes in synaptic strength and architecture. Such a model is supported by dramatic demonstrations of the effects of CREB activation

on enhancing forms of long-term memory [2,3] and synaptic plasticity [4,5].

The generality of the CREB-switch model has been specifically questioned by two previous studies at the *Drosophila* motor synapse. These studies indicate that CREB is dispensable for the activity-dependent modulation of bouton number at the *Drosophila* larval NMJ [6], a process that shares compelling mechanistic similarities to morphological changes required for long-term facilitation in *Aplysia*. Because activity-induced synaptic growth in *Aplysia* requires new neuronal gene expression [7], it was likely that a yet-to-be-identified transcription factor acted to control a CREB-independent gene expression module required for synaptic growth. A recent study suggests that this transcription factor may be AP1 [8], a transcription factor previously shown to be CREB responsive [9–11], essential for some forms of long-term memory [12,13], and for long-term cocaine sensitization [14]. This recent analysis shows that AP1 activity in the *Drosophila* CNS, under regulation by endogenous JNK signalling, regulates both bouton number and synaptic strength at the larval motor synapse. AP1-mediated synaptic growth occurs through a mechanism independent of CREB; however, AP1-mediated increase in synaptic strength (evoked transmitter release) requires CREB. Increased levels of CREB mRNA detected in heads of *Drosophila* after a brief induction of AP1, suggested that AP1 may act upstream of CREB and that AP1 activation may be sufficient to induced CREB dependent and CREB-independent aspects of plasticity [8].

While provocative, these analyses did not exclude the possibility that AP1 expression in modulatory neurons affect motor synapse plasticity by trans-synaptic signalling mechanisms. Here we present a detailed analysis of the cell autonomy of AP1 functions. Using well characterized markers for motor neurons, and previously reported motor-neuron restricted enhancers carefully documented here, we present new lines of evidence in support of a model in which AP1 functions in the motor neuron and regulates NMJ plasticity via its effects on gene expression in the motor neuron.

## Results

### **Fos and Jun are expressed in motor neurons**


For AP1 to function in motor neurons, both of its constituent subunits, Fos and Jun, must be expressed in these cells. We localized the proteins to motor neurons relative to specific markers.

The X-chromosomal *C380* enhancer in particular has been reported, based on unpublished observations, to specifically mark embryonic and larval motor neurons [15–17]. To confirm and document the expression pattern

of this enhancer, we visualized cells in the *Drosophila* CNS labelled by *C380* driven nuclear green fluorescent protein (NlsGFP). In the ventral ganglion of III instar larvae *C380* appeared highly selective in expression, marking only a subset of cells per hemisegment cells from a large field of neurons identified using the pan-neuronal marker *Elav* (Figures 1A,1B and 1C). In the medial, dorsal surface of the ganglion, that contains identified RP and aCC motor neurons [18], *C380* drives GFP reporter expression in 5 of 6 neurons that could be detected in each hemisegment (the neuron not labelled by *C380* is indicated by an asterisk in Figure 1C). Away from this medial zone, in the lateral zones, several cells marked by *C380* appeared negative for *Elav* staining (Figures 1A,1B and 1C).


We positively identified all 5 medial, *C380*-expressing cells as motor neurons using two lines of evidence. First, the aCC (arrow in Figure 1C) and RP2 (arrowhead in Figure 1C) motor neurons identified by anti-*Eve* staining [17] were among the 5 *C380* expressing neurons (data not shown). Second, and more conclusively, Rhodamine-dextran backfills of the entire peripheral nerve bundle (including both the ISN and SN) that innervates abdominal segment A6 clearly marked 5 medial motor neurons per hemisegment. Of the three contralateral MNs, two are RP3 and RP5; the two ipsilateral ones are aCC and RP2 [18,19]. In double "stained" preparations, these same 5 cells are also marked by *C380* reporter expression (Figure 1D). *C380* driven soluble GFP, beautifully labelled presynaptic nerve terminals on the larval body wall muscle further confirming expression in the large majority of motor neurons in the central nervous system (Figure 1L).

To assess the time at which *C380* expression starts, we stained *C380*-GAL4; UAS-NGFP embryos at various stages with anti-*elav* to mark differentiated neurons (Figure 1K). GFP expression in the CNS starts at very late stages (beyond stage 17, data not shown) in embryogenesis and there is no discernible GFP expression even at stage 15 by which time motor neuron differentiation has already taken place. This suggests that in our experiments, AP1 activation or inhibition in differentiated motor neurons is sufficient to cause changes at their synapses. To further test if *C380* expression in embryonic stages or earlier larval instars occurs transiently in a broader domain, we did the following experiment. *C380*; UAS-*cd8GFP* males were crossed to virgin females containing UAS-*FLP* and *actin-FRT-raf-FRT-n lacZ*. In the progeny, *cd8-GFP* would report current *C380* expression. On the other hand, any cell that has seen significant GAL4 expression during the development of the animal, would express the flippase recombinase. In such a cell, the stuffer *raf* fragment would be excised out using the flanking FRT sites, leading to nuclear-*lacZ* expression from the actin promoter [20]. Figure 1M shows the general expression of *n lacZ* in a third



**Figure 1**

**Fos and Jun are expressed in motor neurons marked by the C380 enhancer.** In third-instar larval ventral ganglia, C380 enhancer-driven nuclear GFP (A) marks the dorso-medial cells labelled with the neuronal marker Elav (B and C) and (D) by retrograde fills of the motor nerve (cells circled by a yellow line; cells with a green boundary represent the complementary neurons on the adjoining hemisegment). An arrowhead marks RP2 and an arrow marks aCC in IC. An asterisk marks a dorsal medial neuron not labelled by C380. Both Fos (F) and Jun (I) are expressed strongly in medial motor neurons marked by the C380 enhancer (E and H). Figure IG and IJ are merged images of the above showing Fos and Jun expression in identified C380 positive motor neurons. Fos and Jun are also expressed at lower levels in other neurons and non-neuronal cells including CNS glia (not shown). IK shows a stage 15 embryo expressing C380-Nls-GFP (green) counterstained with anti-elav (red) to mark all differentiated neurons. GFP expression is only seen in PNS neurons (arrowhead) and in salivary gland (asterisk). C380 driven GFP can be detected at high levels at motor synapses in the third instar larva such as that on muscles 6 and 7 (L). The synapse is counterstained with anti-synaptotagmin to mark synaptic boutons (arrowhead). Figure IM shows a third instar ventral ganglion stained for nuclear lacZ. This expression pattern closely mimics that of C380-GAL4. In this animal, lacZ is expressed from an actin promoter only in cells in which "flip-out" of a stuffer DNA has occurred due to C380-GAL4 driven UAS-FLP. Figure IN shows C380 driven membrane bound cd8-GFP expression in the dorsal medial region of a third instar ventral ganglion. IO shows n-lacZ in the same animal and IP is a merged image showing that n-lacZ is expressed only in the motor neurons that are also positive for C380 expression at this developmental stage. The specificity of the Fos antibodies is shown by increased immunoreactivity in motor neurons when API is expressed under control of the C380 enhancer (Q and R). The dashed yellow lines in all cases approximately mark the midline.



**Figure 2**  
**The OK6 enhancer is predominantly restricted to motor neurons while the Cha (cholineacetyltransferase) enhancer is largely excluded from these cells.** Images of ventral ganglia double labelled to reveal *OK6* enhancer driven nuclear GFP (A) and *Elav*-expressing neurons (B). Similar images of ventral ganglia processed to compare *Cha*-driven *n* GFP (D) with *Elav*-labelled neurons (E). *Cha*-GAL4 expression in aCC neurons is shown by an arrowhead in 2D, E and F. Neuromuscular junctions (muscles 6 and 7) of animals expressing GFP under *OK6* control show strongly fluorescent motor terminals (G). Figure 2H shows a stage 15 embryo expressing nuclear GFP driven by *OK6*-GAL4, counterstained with anti-*elav* to mark all differentiated neurons. GFP expression is only seen in salivary gland (asterisk) and some non-neuronal cells (arrowhead).

instar ventral ganglion from such an animal. This expression pattern, a memory of GAL4 expression through development, is highly reminiscent of the C380 profile. Figure 1N, 1O and 1P show a close-up of the dorsal medial region. All motor neurons that are labelled with *cd8*-GFP also have strong *nlacZ* labelling. Taken together, these results strongly suggest that the C380 expression in motor

neurons occurs after their differentiation and in a profile that is stable through development.

Using affinity-purified antibodies against the respective proteins [21], we discovered strong expression of *Fos* and *Jun* in dorsal motor neuron clusters marked by C380 expression (Figures 1E, 1F, 1G, 1H, 1I, 1J). While the

proteins were also found in most other neurons and in glia, expression in motor neurons was particularly strong. The specificity of the antibody and the effectiveness of *C380* in driving Fos and Jun expression are both demonstrated by dramatically increased Fos and Jun immunoreactivity in neurons of flies overexpressing *AP1* (eg. Figures 1Q and 1R). Thus, Fos and Jun are well positioned for autonomous function in presynaptic plasticity of the *Drosophila* NMJ.

#### **Other enhancers that mark or exclude *Drosophila* larval motor neurons**

In addition to *C380* at least two other enhancers have value for restricting transgene expression to (or excluding expression from) motor neurons (Figure 2). The *OK6* enhancer line has been recently reported to be motor neuron specific [22]. In contrast, the recently mapped cholinacetyltransferase (*Cha*) promoter labels cholinergic neurons and may be expected to exclude motor neurons [23,24]. Relatively strong expression of this enhancer in the nervous system is argued by the observation that it causes a strong loss-of-function phenotype when used to drive a dominant-negative *shibire<sup>ts</sup>* transgene [25]. We used methods similar to those used for analysis of *C380* to confirm the expected patterns of expression for these enhancers.

*OK6* driven green nuclear fluorescent protein (GFP) labelled medial motor neurons previously identified with *C380* (Figures 2A,2B and 2C); the identification of these cells was unambiguous. However, motor neuron expression was further confirmed by strong labelling of motor terminals by *OK6* driven GFP marker (Figure 2G). *OK6* expression in the rest of the ventral ganglion appeared distinct from and sparser than that observed with *C380* (Figures 2A,2B,2C). In these animals, similar to *C380*, expression does not start until very late in embryogenesis. Figure 2H shows a stage 15 embryo expressing NGFP driven by *OK6-GAL4*, counterstained with anti-*elav*. Apart from expression in the salivary gland (asterisk) and some non-neuronal cells (arrowhead) expression of GFP in the CNS is completely absent. In contrast to *OK6*, the *Cha* promoter predominantly labelled cells in the lateral region of the ventral ganglion (Figure 2D,2E and 2F). Additional expression was observed in two neurons in the region of the medial motor neuron cluster. One of these is aCC as it is marked by anti-*eve* antibodies and is also labelled by backfills from motor axon bundles (data not shown). The other neuron is most likely an interneuron as it is not labelled by the backfill and is also excluded from *C380*-nlsGFP expressing ganglia. Additionally, *Cha*-driven GFP did not label motor terminals on muscles 6 and 7 (data not shown) indicating that even if it were expressed in some motor neurons, it was excluded from

the motor neurons innervating ventral longitudinal muscles.


Together, these analyses of *C380*, *OK6* and *Cha* expression allow us to reach the following conclusions. First, *C380* and *OK6* are each expressed in a small fraction of neurons in the CNS. Both *C380* and *OK6* are expressed in larval motor neurons, particularly in those that innervate the ventral longitudinal muscles 6 and 7. Secondary expression in non-motor neurons, not excluded by our analyses, appears to be both limited and largely non-overlapping between *C380* and *OK6*. The *Cha* promoter on the other hand is not expressed in the vast majority of motor neurons but nevertheless is strongly expressed in a significant fraction of the central nervous system.

#### **Perturbation of *AP1* in motor neurons regulates NMJ plasticity**

Previous analyses showing that pan-neural perturbations of *AP1* influence both motor synapse number and strength, do not rule out the possibility that the observed effects of this transcription factor on motor neuron plasticity occur via a polysynaptic pathway. If *AP1*'s effects on presynaptic plasticity were cell autonomous, then these effects should be observed by *AP1* perturbation specifically in motor neurons but not following similar perturbation of *AP1* function outside of these cells.

Our analysis of changes in bouton number and evoked transmitter release induced by *C380*-driven or *OK6*-driven dominant *AP1*-transgenes is completely consistent with cell autonomous effects (Figure 3A,3B, Table 1). *C380*-driven Fos inhibitor (FBZ) reduces synaptic strength to about 50+/-7% and bouton number to 75+/-3% of control animals. Thus, *AP1* activity is required in *C380* positive cells for normal developmental plasticity. More striking, *C380*-driven wild-type *AP1* increases synaptic strength to 143+/-12% and bouton number to 123+/-5% of control. These results, significant to better than 99% confidence, are comparable to or, in some cases, more robust than, what we have previously reported for effects of pan-neural, *elav* (*C155*) enhancer driven expression of these same *AP1*-perturbing transgenes [8]. The conclusion from this experiment, that *AP1* functions autonomously in motor neurons to regulate both structural and functional aspects of presynaptic plasticity is limited only by potentially important contributions of *AP1* perturbation in *C380* expressing cells that are not motor neurons.

To address this caveat, we analyzed effects of *OK6* driven, *AP1*-perturbing transgenes on motor synapse plasticity. Results from these experiments were completely consistent with predictions based on the analysis of *C380*. *OK6*-driven FBZ expression resulted in a mean EJC amplitude 55+/-4% and a synapse size 63+3% of wild type. *OK6*-



**Figure 3**

**API effects on NMJ plasticity are tightly correlated with motor neuron expression.** Upper panel shows the effect of inhibition or activation of API in motor neurons using two different motor-neuron GAL4 drivers, *C380* and *OK6*. Representative EJC traces are also shown to highlight the contrasting results of API inhibition or activation. The lower panel shows that similar manipulations in either non-motor neurons (*ChaGAL4*) or post-synaptic muscle (*MHCGAL4*) has minimal effects on synaptic plasticity. Dotted lines represent control levels (for actual values see Table 1). Scale bar: X-axis = 20 msec and Y-axis = 20 nA.



**Table 1: AP1 effects at the larval neuromuscular junction derive from its action in motor neurons. GAL4 drivers that include expression in motor neurons (C155, C380 and OK6) alter synaptic plasticity through either inhibition (FBZ) or activation (AP1) of AP1. Non-motor neuron drivers (Cha) or post-synaptic muscle drivers (MHC) do not achieve this effect. All numbers are raw values (+/- SEM). Numbers in the top left corner of each box are number of animals analyzed in each case. Numbers for C155 are reproduced from Sanyal et al., 2002. Abbreviations: EJC stands for evoked junctional current amplitude, mEJC for miniature evoked junctional current amplitude, and QC is quantal content of the evoked response.**

	C155	C380	OK6	Cha	MHC
<b>Control</b>	(9)	(11)	(7)	(10)	(6)
EJC	108 +/-6	85 +/-3	139 +/-6	90 +/-6	100 +/-8
mEJC	0.76 +/-0.02	0.70 +/-0.03	0.8 +/-0.08	0.75 +/-0.06	0.89 +/-0.05
QC	142 +/-9	122 +/-8	183 +/-16	129 +/-15	115 +/-11
<b>FBZ</b>	(7)	(10)	(6)	(9)	(7)
EJC	80 +/-4	42 +/-6	77 +/-6	79 +/-8	102 +/-4
mEJC	0.78 +/-0.04	0.76 +/-0.05	0.66 +/-0.07	0.89 +/-0.09	0.85 +/-0.03
QC	103 +/-7	56 +/-3	120 +/-11	91 +/-8	122 +/-8
<b>AP1</b>	(9)	(14)	(10)	(10)	(9)
EJC	146 +/-6	121 +/-10	166 +/-11	87 +/-6	91 +/-4
mEJC	0.69 +/-0.05	0.6 +/-0.05	0.65 +/-0.03	0.75 +/-0.1	0.83 +/-0.02
QC	211 +/-12	200 +/-20	261 +/-17	127 +/-14	112 +/-7

driven AP1 expression caused the expected increase in size and strength (EJC was 119+/-7% and synapse size 114+/-5% of wild type).

The relatively mild effect that OK6-driven AP1 has on synapse growth and strength may be explained by lower activity of the OK6 enhancer. However, the effect is unequivocal ( $p < 0.006$  for synapse size and  $< 0.01$  for EJC) and consistent with analysis of C380 driven or pan-neuronal expression of AP1.

#### **AP1 perturbation in cholinergic neurons or in muscle does not alter the NMJ**

We performed additional experiments to confirm that induction of AP1 perturbing transgenes in cholinergic CNS neurons did not alter synapse size or strength at the NMJs on muscles 6 and 7 (Figure 3C, Table 1). *ChaGal4* driven AP1 inhibitory and inducing transgenes had no effect on bouton number or synaptic strength at the larval nmj. In percent of control, values of synaptic strength and bouton number for *ChaGal4 FBZ* are 99+/-4% and 90+/-8%, and for *ChaGal4 AP1*, 98+/-5% and 97+/-7%, respectively. We had previously reported, based on unpublished observations, that postsynaptic expression of AP1 modulating transgenes did not alter motor neuron plasticity [8]. Results for consequences of expressing FBZ or AP1 in muscle through the *Myosin Heavy Chain* enhancers are shown in Figure 3D and Table 1. Muscle expression of FBZ resulted in bouton number and EJC amplitudes of 113+/-5% and 102+/-4%, statistically indistinguishable from the control NMJs. Similarly, muscle expression of AP1 gave values of 92+/-4% for bouton number and 93+/-4% for EJCs. These results further restrict the range of cells in

which AP1 must function in order to influence motor synapse plasticity.

#### **Discussion**

While the role of neural activity, cAMP, adenylate cyclase, ERK, CREB and AP1 in *Drosophila* NMJ plasticity has been extensively analyzed [6,8,16,26,27], the cells in which these regulatory molecules must function for synaptic plasticity have generally not been clearly identified. Here, using an approach that could be usefully adapted for analysis of other components of synaptic plasticity, we provide a compelling argument for a model in which AP1 functions cell autonomously in motor neurons to regulate NMJ plasticity in *Drosophila*.

Caveats to this conclusion derive from uncertainties intrinsic to the use of specific neuronal enhancers to address issue of tissue or cell specificity. Our analyses of the expression patterns of two enhancers unambiguously establish several important points. Both C380 and OK6 are highly expressed in motor neurons [16,17,22]. Secondary expression of these enhancers outside of motor neurons, if present, is first limited and second quite different for the two enhancers (Figures 1 and 2). Thus, common phenotypes caused when AP1 transgenes are expressed by either OK6 or C380 likely result from expression in the neurons positive for both enhancers, i.e. the motor neurons.

It is necessary to acknowledge that our analyses of the expression patterns for C380 and OK6, being confined to the III instar larval stage, do not in themselves rule out the possibility that these enhancers are transiently turned on,

at earlier stages of development, in critical neurons that modulate plasticity processes in motor neurons. While this remains a formal possibility, it seems unlikely for three reasons. First, our experiment with actin-*raf*-*nLacZ* to visualize the history of GAL4 expression in C380 animals shows that it is quite stable and similar to the final expression pattern seen in the third instar ventral ganglia (Figure 1M,1N,1O,1P). Second, because GFP is a notoriously stable reporter molecule [28] we would expect even biologically transient enhancer activity to be revealed by stable reporter expression. Third, both *OK6* and *C380* enhancers become active relatively late in embryogenesis (Figure 1K and 2H) and their expression patterns in embryos is highly similar to that observed in third-instar larvae (data not shown).

A cell-autonomous function for AP1 in motor neurons is also supported by two further lines of independent evidence. First, expression of the same transgenes via the *Cha* enhancer that identified CNS cholinergic neurons or post-synaptic muscle enhancers, have no effect on motor synapse plasticity. One possibility that the negative data for the *Cha* enhancer reflects its low expression level is refuted by its documented ability to drive dominant negative transgenes at levels sufficient to induce a loss of function phenotype for the highly expressed *shibire* (dynamitin) gene [25,29]. Second, immunocytochemical analyses (Figure 1) provide strong evidence for AP1 function in motor neurons. Taken together, the data presented here provide new and important evidence to support a model in which AP1 regulates motor neuron plasticity through a cell autonomous pathway.

## Conclusions

Results presented here make the following points. 1. Fos and Jun are expressed in *Drosophila* larval motor neurons; this establishes that AP1 is appropriately localized for cell autonomous function in motor synapse plasticity. 2. Motor-neuron restricted expression of AP1 perturbing transgenes via several alternative Gal4 drivers results in previously described plasticity effects. 3. AP1 perturbation outside of motor neurons has little effect on NMJ plasticity. Together, these data substantially strengthen a model in which AP1 acts in a cell autonomous pathway that regulates CREB-dependent and CREB-independent aspects of NMJ plasticity [6,8].

## Methods

### *Drosophila* strains and culture conditions

*Drosophila* strains were cultured as previously described [8,30]. The wild-type Oregon-R strain has been maintained in the Ramaswami lab. The *UASFos*, *UASJun* and *UASFBZ* strains from Dr. Mariann Bienz have been previously characterized for roles in NMJ plasticity [8]. The *UASNlsGFP* (encoding GFP tagged with a nuclear localiza-

tion signal) strain was from the *Drosophila* stock center and the 2X-EGFP strain was from Haig Keshishian. Strains with *C380*, *OK6*, *Cha* and *MHC* enhancer driven *Gal4* transgenes were from Vivian Budnik, Brian McCabe, Toshi Kitamoto and Corey Goodman respectively. UAS-FLP is from the Bloomington Stock Center and actin-*raf*-*nLacZ* flies were obtained from Veronica Rodrigues and have been described in [20].

### Generating experimental and control animals

Males from transgenic (driver) lines expressing *Gal4* under control of the various enhancers, were crossed to virgin females from strains (responders) homozygous for the following transgenes: *UAS2XEGFP*, *UASNlsGFP*, *UASFBZ*, *UASAP1* (*UASFos*; *UASJun*). Female larvae carrying both the *Gal4* and Gal4-responsive transgenes were analyzed. These were compared to female progeny from crossing Gal4 driver males to wild-type Oregon R virgin females.

### Immunohistochemistry and confocal microscopy

For examining CNS expression larvae were dissected in standard HL3 ringers and fixed in sodium phosphate buffer containing 0.1% Triton X-100 and 4% paraformaldehyde for one hour at 4°C. Preparations were washed 3 times for 10 minutes each in phosphate buffer (0.1 M Na<sub>2</sub>HPO<sub>4</sub> and 0.1 M NaH<sub>2</sub>PO<sub>4</sub>) and incubated in appropriately diluted primary antibody overnight at 4°C. This was followed by 6 washes of 10 minutes each with phosphate buffer and incubation in Alexa dye (Molecular Probes, OR) conjugated secondary antibody for one hour at room temperature. Finally, the preparations were washed 6 times again in phosphate buffer, then once in normal phosphate buffered saline (PBS) and mounted in vectashield (Vector Labs.) on superfrost charged glass slides (VWR) for confocal microscopy. Laser scanning confocal microscopy was performed on a Nikon confocal microscope. Maximum projections were generated from stacks collected with a spacing of 1.5 μ in all cases. Images were further processed for presentation using Adobe Photoshop. Embryo histochemistry was according to standard procedures as described in "Drosophila, A Laboratory Manual" by Michael Ashburner, CSHL Press.

### Retrograde nerve filling to identify motor neurons

Larvae were anesthetized by chilling on ice for 3 to 5 minutes, and then, they were pinned with dorsal side up on Sylgard-coated (Dow Corning Co., Midland, MI) petri dishes containing HL3 saline [31]. Larvae were dissected along the dorsal midline. The gut, salivary glands, fat bodies and trachea were removed. For retrograde labelling of the motoneurons, one or both side nerve branches innervating the fifth or sixth abdominal segment were isolated in a petroleum jelly pool to allow the uptake of dye (5% w/v rhodamine-dextran-3000 kD in distilled water;



Molecular Probes, Eugene, OR.) [32]. The rhodamine-dextran-labeled preparations were stored at room temperature (RT) for a maximum of 1 hour, in the dark. Preparations were fixed in 2.5% formaldehyde, 3% sucrose, in PBS, pH 7.3, for 2–5 hour, at RT, in the dark. The preparations were washed in PBS after fixation and mounted in 50% glycerol in PBS.

### Electrophysiology, statistical analyses

Voltage clamp was performed as described previously (Sanyal et al, 2002). Briefly, larvae were dissected in HL3 ringers. Both the voltage sensing (10–15 M $\Omega$ ) and current injecting (5–10 M $\Omega$ ) were heat pulled fiber filled glass capillaries. Excitatory evoked junctional currents (EJCs) were recorded in the TEVC mode using an axoclamp-2B amplifier. The holding potential was -70 mV for all recordings. EJCs were recorded from muscle 6 in abdominal segment 2 following a supra-threshold stimulation to the innervating motor axons at 1 Hz. Mean EJC amplitude was determined by averaging 20 sequential EJCs. Spontaneous events were also monitored for a period of 50 seconds. The mean mini-EJC (mEJC) amplitude was calculated from these traces using the mini-analysis software <http://synaptosoft.com>. Statistical analysis including graphing and test of significance (paired t-tests) were performed in Sigma Plot (Jandel Scientific). Quantal content was calculated by dividing the mean EJC amplitude by the mean mEJC amplitude.

### Authors' contributions

SS carried out the immunohistochemistry for the C380 and Cha-GAL4 experiments and all the electrophysiology in this study. RN carried out the immunohistochemistry for the OK6 experiments. CC carried out the dye fills in the C380, nls-GFP animals. Both SS and MR conceived of the study and participated in its design and coordination. SS and MR drafted the manuscript. All authors approved the final manuscript.

### Acknowledgements

We are grateful to Dirk Bohmann for antibodies against Fos and Jun as well as API transgenic strains. Thanks to Stefan Thor, Vivian Budnik, Brian McCabe and Toshi Kitamoto for *Drosophila* strains and useful insights. The antibody to *Drosophila* elav developed by Gerald Rubin was obtained from the Developmental Studies Hybridoma Bank developed under the auspices of the NICHD and maintained by The University of Iowa, Department of Biological Sciences, Iowa City, IA 52242. Thanks also to Carl Boswell for confocal microscopy and the Ramaswami laboratory for discussions and comments on the manuscript. The work was funded by NIH grants DA13337 and NS34489, and grants from the HFSP, McKnight and Alfred P Sloan Foundations to MR.

### References

- Kandel ER: **The molecular biology of memory storage: a dialog between genes and synapses.** *Biosci Rep* 2001, **21**:565-611.
- Josselyn SA, Shi C, Carlezon W. A., Jr., Neve RL, Nestler EJ and Davis M: **Long-term memory is facilitated by cAMP response ele-**

- ment-binding protein overexpression in the amygdala.** *J Neurosci* 2001, **21**:2404-2412.
- Yin JC, Del Vecchio M, Zhou H and Tully T: **CREB as a memory modulator: induced expression of a dCREB2 activator isoform enhances long-term memory in Drosophila.** *Cell* 1995, **81**:107-115.
- Barco A, Alarcon JM and Kandel ER: **Expression of constitutively active CREB protein facilitates the late phase of long-term potentiation by enhancing synaptic capture.** *Cell* 2002, **108**:689-703.
- Bartsch D, Ghirardi M, Skehel PA, Karl KA, Herder SP, Chen M, Bailey CH and Kandel ER: **Aplysia CREB2 represses long-term facilitation: relief of repression converts transient facilitation into long-term functional and structural change.** *Cell* 1995, **83**:979-992.
- Davis GW, Schuster CM and Goodman CS: **Genetic dissection of structural and functional components of synaptic plasticity. III. CREB is necessary for presynaptic functional plasticity.** *Neuron* 1996, **17**:669-679.
- Bailey CH, Montarolo P, Chen M, Kandel ER and Schacher S: **Inhibitors of protein and RNA synthesis block structural changes that accompany long-term heterosynaptic plasticity in Aplysia.** *Neuron* 1992, **9**:749-758.
- Sanyal S, Sandstrom DJ, Hoeffler CA and Ramaswami M: **AP-1 functions upstream of CREB to control synaptic plasticity in Drosophila.** *Nature* 2002, **416**:870-874.
- Ahn S, Olive M, Aggarwal S, Krylov D, Ginty DD and Vinson C: **A dominant-negative inhibitor of CREB reveals that it is a general mediator of stimulus-dependent transcription of c-fos.** *Mol Cell Biol* 1998, **18**:967-977.
- Sheng M, McFadden G and Greenberg ME: **Membrane depolarization and calcium induce c-fos transcription via phosphorylation of transcription factor CREB.** *Neuron* 1990, **4**:571-582.
- Sheng M and Greenberg ME: **The regulation and function of c-fos and other immediate early genes in the nervous system.** *Neuron* 1990, **4**:477-485.
- Grimm R, Schicknick H, Riede I, Gundelfinger ED, Herdegen T, Zuschratter W and Tischmeyer W: **Suppression of c-fos induction in rat brain impairs retention of a brightness discrimination reaction.** *Learn Mem* 1997, **3**:402-413.
- Mileusnic R, Anokhin K and Rose SP: **Antisense oligodeoxynucleotides to c-fos are amnesic for passive avoidance in the chick.** *Neuroreport* 1996, **7**:1269-1272.
- Kelz MB, Chen J, Carlezon W. A., Jr., Whisler K, Gilden L, Beckmann AM, Steffen C, Zhang YJ, Marotti L, Self DW, Tkatch T, Baranaukas G, Surmeier DJ, Neve RL, Duman RS, Picciotto MR and Nestler EJ: **Expression of the transcription factor deltaFosB in the brain controls sensitivity to cocaine.** *Nature* 1999, **401**:272-276.
- Budnik V, Koh YH, Guan B, Hartmann B, Hough C, Woods D and Gorczyca M: **Regulation of synapse structure and function by the Drosophila tumor suppressor gene dlg.** *Neuron* 1996, **17**:627-640.
- Koh YH, Ruiz-Canada C, Gorczyca M and Budnik V: **The Ras1-mitogen-activated protein kinase signal transduction pathway regulates synaptic plasticity through fasciclin II-mediated cell adhesion.** *J Neurosci* 2002, **22**:2496-2504.
- Marques G, Bao H, Haerry TE, Shimell MJ, Duchek P, Zhang B and O'Connor MB: **The Drosophila BMP type II receptor Wishful Thinking regulates neuromuscular synapse morphology and function.** *Neuron* 2002, **33**:529-543.
- Sink H and Whittington PM: **Location and connectivity of abdominal motoneurons in the embryo and larva of Drosophila melanogaster.** *J Neurobiol* 1991, **22**:298-311.
- Hoang B and Chiba A: **Single-cell analysis of Drosophila larval neuromuscular synapses.** *Dev Biol* 2001, **229**:55-70.
- Struhl G and Basler K: **Organizing activity of wingless protein in Drosophila.** *Cell* 1993, **72**:527-540.
- Zeitlinger J, Kockel L, Peverali FA, Jackson DB, Mlodzik M and Bohmann D: **Defective dorsal closure and loss of epidermal decapentaplegic expression in Drosophila fos mutants.** *Embo J* 1997, **16**:7393-7401.
- Aberle H, Haghghi AP, Fetter RD, McCabe BD, Magalhaes TR and Goodman CS: **wishful thinking encodes a BMP type II receptor that regulates synaptic growth in Drosophila.** *Neuron* 2002, **33**:545-558.

23. Kitamoto T, Ikeda K and Salvaterra PM: **Regulation of choline acetyltransferase/lacZ fusion gene expression in putative cholinergic neurons of *Drosophila melanogaster*.** *J Neurobiol* 1995, **28**:70-81.
24. Kitamoto T: **Conditional disruption of synaptic transmission induces male-male courtship behavior in *Drosophila*.** *Proc Natl Acad Sci U S A* 2002, **99**:13232-13237.
25. Kitamoto T: **Conditional modification of behavior in *Drosophila* by targeted expression of a temperature-sensitive shibire allele in defined neurons.** *J Neurobiol* 2001, **47**:81-92.
26. Budnik V, Zhong Y and Wu CF: **Morphological plasticity of motor axons in *Drosophila* mutants with altered excitability.** *J Neurosci* 1990, **10**:3754-3768.
27. Zhong Y, Budnik V and Wu CF: **Synaptic plasticity in *Drosophila* memory and hyperexcitable mutants: role of cAMP cascade.** *J Neurosci* 1992, **12**:644-651.
28. Triccas JA, Pinto R and Britton WJ: **Destabilized green fluorescent protein for monitoring transient changes in mycobacterial gene expression.** *Res Microbiol* 2002, **153**:379-383.
29. Grant D, Unadkat S, Katzen A, Krishnan KS and Ramaswami M: **Probable mechanisms underlying interallelic complementation and temperature-sensitivity of mutations at the shibire locus of *Drosophila melanogaster*.** *Genetics* 1998, **149**:1019-1030.
30. Krishnan KS, Rikhy R, Rao S, Shivalkar M, Mosko M, Narayanan R, Etter P, Estes PS and Ramaswami M: **Nucleoside diphosphate kinase, a source of GTP, is required for dynamin-dependent synaptic vesicle recycling.** *Neuron* 2001, **30**:197-210.
31. Stewart BA, Atwood HL, Renger JJ, Wang J and Wu CF: **Improved stability of *Drosophila* larval neuromuscular preparations in haemolymph-like physiological solutions.** *J Comp Physiol [A]* 1994, **175**:179-191.
32. Consoulas C, Restifo LL and Levine RB: **Dendritic remodeling and growth of motoneurons during metamorphosis of *Drosophila melanogaster*.** *J Neurosci* 2002, **22**:4906-4917.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:  
[http://www.biomedcentral.com/info/publishing\\_adv.asp](http://www.biomedcentral.com/info/publishing_adv.asp)

